Autopsy report · NCT01421927

Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma

“target number of inclusion not reached”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 2 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

University Hospital, Bordeaux

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma

Interventions

Lenalidomide

Participants

13

Sites

1

Countries

France

Trials that died the same way

• Assessment of Inspiratory Muscles Strength and Endurance Evolution on Difficult to Wean Patients in Intensive Care Unit
  “target number of inclusion no reached” (96% match in meaning)
• Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis
  “inclusion number not sufficient” (74% match in meaning)
• Respiratory Variations for Assessing Blood Withdrawal 2
  “insufficient inclusion rate” (73% match in meaning)
• Video-Assisted Thoracoscopic Pulmonary Vein Isolation Versus Percutaneous Catheter Ablation in Atrial Fibrillation Trial
  “Inclusion rate insufficient” (71% match in meaning)
• Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care.
  “insufficient inclusions” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.